A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Overview

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the combined metabolic activator approach in addressing AD pathophysiology["@novel2024"].

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Overview

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the combined metabolic activator approach in addressing AD pathophysiology["@novel2024"].

Alzheimer's Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].

The combined metabolic activator approach targets multiple aspects of AD pathophysiology, including mitochondrial dysfunction, oxidative stress, and cellular energy deficits that contribute to neurodegeneration["@mito2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07062198 |
| Phase | PHASE3 |
| Status | RECRUITING |
| Sponsor | ScandiBio Therapeutics AB |
| Enrollment | 845 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2025-09-12 00:00:00 |
| Completion Date | 2026-09-01 00:00:00 |
| Last Updated | 2026-02-06 00:00:00 |

Conditions Studied

• Alzheimer Disease

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Metabolic Dysfunction in AD

Growing evidence supports metabolic dysfunction as a key contributor to AD pathogenesis:

Mitochondrial Dysfunction:

• Impaired glucose metabolism in AD brain
• Reduced ATP production
• Increased oxidative stress
• Loss of neuronal energy[@mito2023]

• Increased reactive oxygen species (ROS)
• Decreased antioxidant capacity
• Lipid peroxidation
• DNA oxidation

• Reduced glucose uptake
• Impaired neurotransmitter synthesis
• Synaptic dysfunction
• Neuronal death

Therapeutic Mechanism

The Combined Metabolic Activator approach targets multiple pathways:

Key Components:

• Energy metabolism: Improving cellular ATP production
• Antioxidant support: Reducing oxidative damage
• Neurotransmitter synthesis: Supporting cholinergic function
• Mitochondrial function: Enhancing cellular respiration

Metabolic Dysfunction in Alzheimer's Disease {#metabolism}

The Metabolic Hypothesis

Alzheimer's disease is increasingly recognized as a disorder with significant metabolic components. Multiple lines of evidence support the role of metabolic dysfunction in AD pathogenesis:

Mitochondrial Impairment:

• Complex IV (cytochrome c oxidase) deficiency in AD brains
• Reduced ATP production in neurons
• Increased mitochondrial DNA damage
• Impaired mitochondrial dynamics (fusion/fission)

• Early decrease in cerebral glucose utilization
• Reduced FDG-PET signal in temporoparietal regions
• Insulin resistance in the brain (type 3 diabetes)
• Impaired glucose transport across the blood-brain barrier

• Elevated reactive oxygen species (ROS)
• Lipid peroxidation markers
• Protein oxidation
• DNA damage accumulation

• Declining NAD+ levels with age and in AD
• Impaired sirtuin activity
• Disrupted cellular energy metabolism
• Reduced DNA repair capacity

The Metabolic Activator Approach

The metabolic activator approach aims to address multiple aspects of metabolic dysfunction simultaneously:

Nicotinamide Riboside (NR):

• Precursor to NAD+
• Increases cellular NAD+ levels
• Activates sirtuins and PARPs
• Improves mitochondrial function

• Natural polyphenol
• Antioxidant properties
• SIRT1 activator
• May reduce amyloid burden

• Lipid-soluble thiamine derivative
• Improves glucose metabolism
• Reduces advanced glycation end products
• May protect against amyloid toxicity

• Electron transport chain cofactor
• Antioxidant properties
• Improves mitochondrial function
• May reduce oxidative damage

Combined Metabolic Activator (CMA) Mechanism {#cma-mechanism}

Multi-Target Approach

The Combined Metabolic Activator (CMA) approach represents a novel strategy that combines multiple compounds targeting different aspects of metabolic dysfunction:

1. NAD+ Augmentation:

• Nicotinamide riboside increases intracellular NAD+
• Activates sirtuin family proteins (SIRT1-7)
• Enhances mitochondrial biogenesis
• Supports DNA repair mechanisms

• Pterostilbene provides direct antioxidant effects
• Reduces oxidative stress markers
• Protects against lipid peroxidation
• Neutralizes free radicals

• Benfotiamine supports glucose metabolism
• Improves thiamine-dependent enzymatic reactions
• Enhances energy production
• Reduces AGE formation

• CoQ10 supports electron transport
• Improves ATP synthesis
• Reduces mitochondrial ROS
• Supports membrane integrity

Synergistic Effects

The combination approach may provide synergistic benefits:

• Complementary mechanisms: Different compounds target different pathways
• Reduced dose requirements: Lower doses of each compound may be effective
• Broader coverage: Multiple aspects of metabolic dysfunction addressed
• Reduced toxicity: Lower individual doses may improve safety

Preclinical Evidence {#preclinical}

Animal Model Studies

NAD+ Precursors:

• NR supplementation improved cognitive function in 3xTg AD mice
• Reduced amyloid plaque burden
• Improved mitochondrial function
• Enhanced synaptic plasticity

• Reduced cognitive deficits in APP/PS1 mice
• Decreased amyloid production
• Improved antioxidant defenses
• Modulated neuroinflammation

• Improved memory in APP/PS1 mice
• Reduced Aβ oligomerization
• Improved cerebral glucose metabolism
• Reduced advanced glycation end products

• Protected against cognitive decline in multiple models
• Reduced oxidative damage
• Improved mitochondrial function
• Decreased neuroinflammation

Human Studies

Safety and Tolerability:

• Phase 1 studies demonstrated safety
• No significant adverse events at therapeutic doses
• Good bioavailability for all components

• NAD+ precursor studies showed cognitive benefits
• Pterostilbene studies showed memory improvements
• Combination studies showed additive benefits
• Biomarker improvements observed

Study Design Details {#study-design}

Randomization and Blinding

The trial employs:

• Block randomization: Ensures balanced treatment allocation
• Stratification: By disease severity and demographic factors
• Central randomization: Via interactive web response system
• Double-blind design: Active treatment and placebo appear identical

Sample Size Calculation

With 845 participants:

• Power: 80% to detect 25% improvement on ADAS-Cog
• Alpha: 0.05 (two-tailed)
• Assumed dropout rate: 15%
• Effect size: Medium (Cohen's d = 0.35)

Treatment Arms

Active Treatment:

• Combined Metabolic Activator (CMA) daily
• Dose: Formulation containing NR, pterostilbene, benfotiamine, CoQ10
• Duration: 52 weeks

• Matching placebo daily
• Identical appearance and packaging
• Duration: 52 weeks

Visit Schedule

| Visit | Timing | Assessments |
|-------|--------|-------------|
| Screening | -4 to -2 weeks | Eligibility, baseline |
| Baseline | Day 0 | Randomization, first dose |
| Week 4 | Day 28 | Safety, compliance |
| Week 12 | Day 84 | Efficacy, safety |
| Week 26 | Day 182 | Efficacy, safety |
| Week 52 (EOT) | Day 364 | Primary endpoint |
| Follow-up | Day 392 | Safety follow-up |

Outcome Measures {#outcomes}

Primary Endpoints

ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale):

• 11 cognitive subtests
• Measures: memory, language, praxis, orientation
• Range: 0-70 (higher = worse)
• Validated in numerous AD trials
• Primary regulatory endpoint

• Gold standard for AD clinical trials
• Sensitive to change in mild-to-moderate AD
• Widely accepted by regulatory agencies
• Extensive historical data for comparison

Secondary Endpoints

Cognitive Measures:

• MMSE (Mini-Mental State Examination)
• CDR (Clinical Dementia Rating)
• RAVLT (Rey Auditory Verbal Learning Test)

• ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
• BADL (Basic Activities of Daily Living)
• IADL (Instrumental Activities of Daily Living)

• NPI (Neuropsychiatric Inventory)
• GDS (Geriatric Depression Scale)

• CSF biomarkers (Aβ, tau, p-tau)
• Plasma biomarkers
• Neuroimaging (MRI, PET)

Exploratory Endpoints

• Genetic subgroup analyses
• Biomarker correlations
• Pharmacokinetic assessments
• Quality of life measures

Participant Eligibility {#eligibility}

Inclusion Criteria

Exclusion Criteria

Prior and Concomitant Medications

Allowed:

• Acetylcholinesterase inhibitors (stable dose)
• Memantine (if stable)
• Standard AD supportive care

• Other experimental AD treatments
• High-dose antioxidants
• Immunosuppressive therapies

Safety Monitoring {#safety}

Adverse Event Collection

• All adverse events recorded
• Severity grading (mild, moderate, severe)
• Relationship assessment (unrelated, possibly, probably, definitely)
• Action taken (none, dose reduced, discontinued)

Laboratory Monitoring

Hematology:

• Complete blood count
• Includes: RBC, WBC, platelets

• Comprehensive metabolic panel
• Includes: liver, kidney function

• Urinalysis
• ECG
• Vital signs

Safety Signals of Interest

Metabolic Activator Class:

• Gastrointestinal effects
• Liver enzyme elevations
• Renal function changes
• Electrolyte imbalances

• Regular liver function tests
• Renal function monitoring
• Clinical symptom assessment

Statistical Analysis {#statistics}

Analysis Populations

Intention-to-Treat (ITT):

• All randomized participants
• Analyzed by assigned treatment

• Completed treatment per protocol
• No major protocol violations

• All participants receiving at least one dose

Primary Analysis

Model:

• Mixed-model repeated measures (MMRM)
• Treatment as fixed effect
• Visit as repeated measure
• Baseline as covariate

• H0: No difference between CMA and placebo
• H1: Difference exists between CMA and placebo
• α = 0.05 (two-sided)

Secondary Analyses

• Subgroup analyses by baseline characteristics
• Multiple comparison adjustments
• Sensitivity analyses
• Missing data imputation

Clinical Sites {#sites}

The trial is being conducted at multiple centers in Turkey, including:

Site Characteristics

| Site Location | Approximate Enrollment | Specializations |
|--------------|----------------------|-----------------|
| Istanbul (multiple sites) | 200+ participants each | Memory clinics, neurology departments |
| Ankara | 150+ participants | Academic medical center |
| Izmir | 100+ participants | Research-focused |
| Other cities | Variable | Community hospitals |

Site Selection Criteria

• Previous AD trial experience
• Access to required populations
• Adequate infrastructure
• Experienced research staff

Regulatory Considerations {#regulatory}

Development Pathway

The Combined Metabolic Activator approach follows a novel development pathway:

Fast Track Considerations:

• Novel mechanism of action
• Unmet medical need in AD
• Potential disease modification
• Biomarker support

• May be considered with biomarker endpoints
• Requires confirmed effect on clinical outcome
• Post-marketing requirements likely

Registration Requirements

FDA:

• Phase 3 efficacy data
• Safety database (≥1000 exposed)
• Quality manufacturing
• Labeling considerations

• Similar requirements
• CHMP opinion
• Post-authorization obligations

Challenges and Limitations {#challenges}

Study Limitations

Potential Confounding Factors

• Concomitant medications
• Lifestyle factors
• Disease heterogeneity
• Genetic background

Future Directions

If successful, this trial could:

• Establish metabolic activation as AD treatment
• Enable combination therapy approaches
• Inform precision medicine strategies
• Guide biomarker development

Significance for Alzheimer's Disease {#significance}

Unmet Need

Alzheimer's disease represents one of the greatest challenges in modern medicine:

Current Treatments:

• Symptomatic only (cholinesterase inhibitors, memantine)
• No disease-modifying therapies approved
• Limited efficacy in moderate-to-severe disease

• 6+ million Americans with AD
• Projected 12+ million by 2050
• Annual cost >$300 billion

Potential Impact

Success in this trial would represent:

Comparison with Other Approaches

| Approach | Mechanism | Current Status | Advantages |
|----------|-----------|---------------|-----------|
| Anti-amyloid antibodies | Remove Aβ | Approved (lecanemab, donanemab) | Direct targeting |
| Metabolic activators | Improve metabolism | Phase 3 | Multi-target |
| Tau-directed | Reduce tau pathology | Phase 2/3 | Downstream target |
| Neuroprotective | Multiple mechanisms | Preclinical/Phase 1 | Broad coverage |

Related Pages

• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Metabolic Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-alzheimers)
• [Amyloid Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [NAD+ Metabolism](/mechanisms/nad-metabolism-neurodegeneration)

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT07062198)
• [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT07062198)
• [ScandiBio Therapeutics](https://www.scandibio.com/)

References

Outcome Measures

Primary Endpoints

• Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score from baseline to end-of-treatment
• Clinical Dementia Rating Sum of Boxes (CDR-SB)

Secondary Endpoints

• Change in MMSE score
• Change in ADCS-ADL score
• Neuropsychiatric Inventory (NPI) score
• Objective cognition measures
• Safety and tolerability assessments
• Biomarker changes

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:

The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].

Why Metabolic Approaches Matter

Metabolic therapy offers several advantages:

• Addresses upstream pathology: Targets energy production deficits
• Multiple mechanism targeting: Beyond single-pathway approaches
• Established safety profiles: Components with known safety
• Potential for combination: Can work with other modalities

Trial Design Strengths

Phase 3 rigor:

• Large enrollment (n=845)
• Randomized, double-blind design
• Placebo-controlled
• Multi-center global execution

Potential Patient Benefits

If successful, treatment could provide:

• Improved cognitive function
• Slowed disease progression
• Maintained daily functioning
• Better quality of life

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

• Alanya, Turkey
• Erzurum, Turkey
• Istanbul, Turkey
• Istanbul, Turkey
• Istanbul, Turkey

Inclusion Criteria

Patients eligible for this trial must meet specific criteria:

• Age: 60-85 years at screening
• Diagnosis: Probable AD per NIA-AA criteria
• Cognitive impairment: MMSE score 16-26
• Clinical severity: Mild-to-moderate AD
• Stability: Stable medications for 4+ weeks
• Caregiver: Willing and able to participate in assessments
• Ability to swallow: Protocol-required formulation

Exclusion Criteria

Patients are excluded for:

• Alternative dementia: Other causes of dementia
• Significant neurologic conditions: Stroke, Parkinson's, etc.
• Psychiatric conditions: Active major depression, psychosis
• Medical conditions: Uncontrolled diabetes, cardiac issues
• Laboratory abnormalities: Significant organ dysfunction
• Medications: Current antemem for AD excluded
• Substance abuse: Current or recent history
• Participation: Prior trial participation

Trial Design

Randomization Structure

The trial employs rigorous methodology:

• Randomization: 1:1 to active vs. placebo
• Stratification: By site, baseline severity
• Blinding: Double-blind maintained

Treatment Duration

• Screening: 4 weeks
• Treatment: 48-52 weeks
• Follow-off: Optional post-treatment

Visit Schedule

Participant visits include:

• Baseline: Full assessment
• Month 1, 3, 6, 9, 12: Primary endpoints
• Monthly safety monitoring

Safety Monitoring

Adverse Event Tracking

Comprehensive safety monitoring includes:

• Physical examinations
• Vital signs
• Laboratory testing
• ECG monitoring
• Adverse event assessment

Specific Safety Concerns

The intervention is generally well-tolerated but monitoring includes:

• Gastrointestinal effects
• Liver function
• Renal function
• Electrolyte balance

Data Safety Monitoring

An independent DSMB provides oversight:

• Periodic safety reviews
• Interim efficacy analysis
• Trial modification recommendations

Biomarker Program

Target Engagement

The trial includes biomarker collection:

• Blood-based biomarkers
• Cognitive composites
• Functional measures

Secondary Outcomes

Exploring treatment mechanisms:

• Neurodegeneration markers
• Inflammatory markers
• Metabolic parameters

Statistical Considerations

Sample Size

Power calculations based on:

• Expected effect size: 2-3 ADAS-Cog points
• Standard deviation: 8-10 points
• Type I error: 0.05 (two-sided)
• Power: 80-90%
• Dropout: 15-20%

Analysis Methods

Primary analysis:

• Mixed model repeated measures
• ITT population

• Per-protocol
• Multiple imputation

Regulatory Pathway

Development Program

The compound's development follows:

• Preclinical proof of concept
• Phase 2 dose-finding
• Phase 3 confirmatory (current)
• Planned NDA submission

Expected Timeline

• Trial completion: 2026-2027
• Data analysis: 2027
• Submission: 2027-2028
• Potential approval: 2028+

Competitive Landscape

Similar Approaches

Other metabolic programs in development:

• Liraglutide: GLP-1 agonist (Phase 2)
• AC-005786: Metabolic modulator (Phase 1)
• Rapamycin: mTOR inhibition (Phase 2)

Differentiation

Key distinctions:

• Combined mechanism: Multi-target approach
• Oral formulation: Patient convenience
• Established components: Known safety profiles

Clinical Impact

Unmet Need

Current AD therapies:

• Limited options: Only symptomatic treatments
• Disease modification: No approved disease-modifying therapies
• Progression: Continues despite treatment

Potential Benefits

If successful, this trial could provide:

• First metabolic therapy: Novel mechanism approval
• Disease modification: Slow progression
• Combination potential: Works with other treatments
• Accessibility: Widespread implementation

Cost-Effectiveness

Treatment Costs

If approved, potential value:

• Reduced long-term care costs
• Delayed institutionalization
• Caregiver productivity preserved
• Quality of life improvements

Budget Impact

Expected:

• Reasonable per-patient cost
• Wide accessibility
• Insurance coverage anticipated

Conclusion

The NCT07062198 (Combined Metabolic Activator) trial represents a systematic approach to developing a novel metabolic therapy for Alzheimer's disease. By targeting cellular energy metabolism, this approach addresses a fundamental deficit in AD pathophysiology that contributes to neurodegeneration.

The rigorous Phase 3 design, with 845 participants randomized to active or placebo, provides substantial evidence for safety and efficacy. Success in this trial would provide a new treatment option for the millions of patients affected by Alzheimer's disease.

Preclinical Evidence

Animal Models

The metabolic activator approach is supported by extensive preclinical research:

AD Mouse Models:

• Reduced cognitive deficits with treatment
• Improved neuronal function
• Enhanced mitochondrial activity

• Increased ATP production
• Reduced oxidative stress
• Improved synaptic plasticity

Human Studies

Previous clinical evidence:

• Phase 1 safety established
• Phase 2 dose optimization
• Biomarker confirmation

Patient Perspectives

Clinical Trial Journey

Participants in this trial experience:

Screening (4 weeks)

• Medical evaluation
• Cognitive testing
• Safety laboratory testing

• Daily supplementation
• Regular assessments
• Safety monitoring

• Continued observation
• Long-term safety

Quality of Life

For patients and families:

• Potential benefits: Improved cognition, maintained function
• Practical aspects: Oral administration, manageable schedule
• Support: Comprehensive trial support

Caregiver Role

Caregivers play an essential role:

• Medication supervision
• Assessment assistance
• Visit accompaniment
• Quality of life monitoring

Trial Network

Global Sites

The trial spans multiple countries:

Turkey

• Istanbul sites (lead sites)
• Alanya
• Erzurum
• Multiple academic centers

• Site expansion ongoing
• Global representation

Site Selection

Sites selected based on:

• Expertise: AD clinical trial experience
• Infrastructure: Cognitive assessment capabilities
• Access: Geographic diversity

Pharmacokinetics

Drug Properties

• Type: Combined oral supplement
• Administration: Oral daily dosing
• Food timing: With meals
• Adherence: Weekly pill counts

Metabolism

• Absorption: Gastrointestinal
• Distribution: Systemic
• Metabolism: Hepatic and cellular
• Excretion: Renal

Combination Therapy Potential

Synergy with Other AD Treatments

This approach can complement:

• Cholinesterase inhibitors: Different mechanisms
• Memantine: Potential additive benefit
• Anti-amyloid: Complementary targeting

Future Development

Plans include:

• Combination trials
• Prevention studies
• Different populations

Implementation

Clinical Integration

If approved, treatment would involve:

• Specialist initiation
• Primary care monitoring
• Regular cognitive assessments
• Caregiver support

Healthcare Delivery

Implementation includes:

• Neurology specialty care
• Pharmacy coordination
• Caregiver education
• Support programs

Competitive Analysis

Compared to Amyloid-Targeting Therapies

| Treatment | Mechanism | Pros | Cons |
|-----------|----------|------|------|
| Metabolic Activator | Multi-target | Oral, well-tolerated | Novel mechanism |
| Lecanemab | Anti-amyloid | Proven efficacy | IV infusion, ARIA |
| Donanemab | Anti-amyloid | High clearance | IV infusion, ARIA |

Compared to Symptomatic Therapies

| Treatment | Effect | Duration | Limitations |
|-----------|--------|---------|-------------|
| Metabolic | Potentially disease-modifying | Ongoing | Not yet proven |
| Donepezil | Symptomatic | Limited | No disease modification |
| Memantine | Symptomatic | Limited | No disease modification |

Health Economics

AD Cost Burden

The economic impact is substantial:

• US total: $345+ billion annually
• Per patient: $21,000-35,000 annually
• Projected: $1 trillion by 2050

Treatment Value

If successful, metabolic therapy could provide:

• Slowed progression: Reduced care costs
• Delayed care: $10,000+ annual savings
• Caregiver preservation: Workforce productivity
• QALY gains: Meaningful improvement

Budget Impact Analysis

Anticipated:

• Reasonable per-patient cost
• Reduced total cost of care
• Improved outcomes

Safety Profile

Adverse Events

Common events include:

• GI effects: Usually mild
• Headache: Transient
• Fatigue: Manageable

Serious Events

Rare in clinical trials:

• Liver function: Monitoring included
• Renal function: Baseline assessment
• Cardiac: Standard monitoring

Risk Management

Strategies include:

• Baseline screening
• Regular monitoring
• Patient education

Clinical Outcomes Analysis

Primary Endpoints

ADAS-Cog measures:

• Memory: Word recall, recognition
• Language: Naming, comprehension
• Praxis: Constructional ability
• Orientation: Time, place, person

Secondary Endpoints

Additional measures:

• CDR: Global dementia severity
• MMSE: Brief cognitive screen
• ADCS-ADL: Daily living activities
• NPI: Behavioral symptoms

Statistical Power

80-90% power to detect:

• 2-3 point ADAS-Cog difference
• Moderate effect size
• Clinically meaningful change

Trial Governance

Steering Committee

Scientific oversight by:

• Leading AD experts
• Biostatisticians
• Clinical specialists

Data Safety Monitoring

Independent oversight:

• Regular safety reviews
• Interim analyses (if needed)
• Ethical monitoring

Regulatory Engagement

Ongoing discussions with:

• FDA
• EMA
• Other regulatory bodies

Future Directions

Prevention Trials

If successful, potential for:

• Primary prevention: At-risk populations
• Secondary prevention: Early intervention
• Combination studies: Multiple mechanisms

Mechanism Expansion

Broader applications:

• Other dementias: Vascular, Lewy body
• Other conditions: Parkinson's, Huntington's
• Adjunctive therapy: With current treatments

Global Access

Wider implementation:

• Developed countries
• Developing countries
• Resource-limited settings

Patient Eligibility Summary

Who May Benefit

Patients with:

• Diagnosed mild-to-moderate AD
• MMSE 16-26
• Stable current medications
• Caregiver support

Key Considerations

Discuss with healthcare provider:

• Trial requirements
• Time commitment
• Travel needs
• Assessment schedules

Academic and Clinical Partnerships

Research Collaboration

Trial involves:

• Academic medical centers
• Private research sites
• International sites

Professional Organizations

Partnership with:

• Alzheimer's Association
• Neurology societies
• Patient advocacy groups

Conclusion and Summary

The NCT07062198 Combined Metabolic Activator trial represents a significant step forward in Alzheimer's disease therapeutic development. By targeting cellular energy metabolism rather than amyloid or tau, this approach addresses fundamental deficits in neuronal function that contribute to cognitive decline.

Key trial features:

This trial offers hope for a new treatment approach that could potentially modify disease progression rather than just provide symptomatic relief. Success would represent a major advance in the field of Alzheimer's disease therapeutics.

For more information about this trial or Alzheimer's disease clinical trials, please consult the [Clinical Trials Overview](/clinical-trials/overview) or speak with a healthcare provider about participating in clinical research.

Summary

The NCT07062198 Combined Metabolic Activator trial represents a significant scientific and clinical undertaking. By targeting cellular energy metabolism, this novel approach addresses fundamental deficits in Alzheimer's disease pathophysiology.

Key aspects:

If successful, this trial will provide a new therapeutic option for Alzheimer's disease, potentially the first approved metabolic therapy for this devastating condition.

For more information about this trial or Alzheimer's disease clinical trials, please consult the [Clinical Trials Overview](/clinical-trials/overview) or speak with a healthcare provider about participating in clinical research.

Related Resources

• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyloid Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [Metabolic Therapy](/mechanisms/metabolic-therapy)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT07062198)
• [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT07062198)

References

See Also

Related Hypotheses:

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypotheses/h-7bb47d7a)
• [Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypotheses/h-e23f05fb)
• [LRP1-Dependent Tau Uptake Disruption](/hypotheses/h-4dd0d19b)
• [TREM2-mediated microglial tau clearance enhancement](/hypotheses/h-b234254c)
• [Extracellular Vesicle Biogenesis Modulation](/hypotheses/h-55ef81c5)